Glycemic Status In Patients Research Articles

Association between RDW-SD and prognosis across glycemic status in patients with dilated cardiomyopathy

IntroductionThe prognostic significance of red cell distribution width-SD (RDW-SD) as a promising inflammatory biomarker in individuals with non-ischemic dilated cardiomyopathy (DCM) and varying glycemic status remains unexplored.Research design and methodsPatients...

Efficacy of Ma'aljobon Aftimouni (Cuscuta Reflexa and Whey) on HbA1c and Blood Glucose Levels in Patients with Type 2 Diabetes: A Randomized Triple-Blind Clinical Trial

Introduction and ObjectiveType 2 Diabetes is a common and chronic metabolic disease. Complementary and alternative medicine can provide a suitable option for demands for new treatments. Therefore, the present study aimed to investigate the effect of Persian medicine on the glycemic status of patients with Type 2 Diabetes. MethodThis randomized, controlled, and triple-blind trial study was conducted from November 2021 to August 2022 on 102 diabetic patients referred to the diabetes clinic in Iran. In this regard, patients with inclusion criteria were randomly divided into three groups Ma'aljobon with Aftimoun (n = 34), Ma'aljobon without Aftimoon (n = 34), and the control group (n = 34). The control group received a placebo of medicinal salt, light calcium carbonate, lactose, and carboxymethyl cellulose. In contrast, the treatment groups received 25 grams of drug powder (in 250 cc of lukewarm water) on an empty stomach for 8 consecutive weeks. Patients' fasting blood sugar (FBS) levels and HbA1c were measured at the beginning and end of the intervention. Data were analyzed using SPSS 23, employing paired t-tests, ANOVA, and chi-square tests for comparison between groups. ResultsData analysis was conducted on 90 patients with Type 2 Diabetes. The findings revealed a significant reduction in fasting blood sugar levels post-intervention in the Ma'aljobon Aftimouni group (134.27± 21.79 vs. 152.3± 31.37, mean difference 18.03± 5.63, 95% CI: 6.53 to 29.53, p = 0.003). Additionally, a significant difference in HbA1c values was observed post-intervention in both the Ma'aljobon Aftimouni group (7.88± 0.77 vs. 8.09± 0.73, mean difference 0.21± 0.09, 95% CI: 0.03 to 0.39, p = 0.031) and the Ma'aljobon without Aftimoun group (7.97± 0.84 vs. 8.25± 0.78, mean difference 0.28± 0.08, 95% CI: 0.11 to 0.45, p = 0.002). ConclusionThe findings showed that daily consumption of Ma'aljobon supplements on an empty stomach before breakfast may have a beneficial effect on the glycemic indices of patients. However, further studies seem to be necessary in this regard.

Evaluating HbA1c-to-average glucose conversion with patient-specific kinetic models for diverse populations.

The discrepancy between estimated glycemia from HbA1c values and actual average glucose (AG) levels has significant implications for treatment decisions and patient understanding. Factors contributing to the gap include red blood cell (RBC) lifespan and glucose uptake into the RBC. Personalized models have been proposed to enhance AG prediction accuracy by considering interpersonal variation. This study contributes to our understanding of personalized models for estimating AG from HbA1c. Utilizing data from seven studies (340 participants), including Hispanic/Latino populations with or at risk of non-insulin-treated type 2 diabetes (T2D), we examined kinetic features across cohorts. Additionally, the study simulated scenarios to understand data requirements for improving accuracy. Personalized approaches improved agreement between AG estimations and CGM-AG, particularly with four or more weeks of training CGM data. A multiple linear regression model using kinetic parameters and added clinical features was shown to improve the accuracy of personalized models further. As CGM usage extends beyond type 1 diabetes, there is growing interest in leveraging CGM data for clinical decision-making. Patient-specific models offer a valuable tool for managing glycemic status in patients with discordant HbA1c and AG values.

Attention to Innate Circadian Rhythm and the Impact of Its Disruption on Diabetes.

Novel strategies are required to reduce the risk of developing diabetes and/or clinical outcomes and complications of diabetes. In this regard, the role of the circadian system may be a potential candidate for the prevention of diabetes. We reviewed evidence from animal, clinical, and epidemiological studies linking the circadian system to various aspects of the pathophysiology and clinical outcomes of diabetes. The circadian clock governs genetic, metabolic, hormonal, and behavioral signals in anticipation of cyclic 24-hour events through interactions between a "central clock" in the suprachiasmatic nucleus and "peripheral clocks" in the whole body. Currently, circadian rhythmicity in humans can be subjectively or objectively assessed by measuring melatonin and glucocorticoid levels, core body temperature, peripheral blood, oral mucosa, hair follicles, rest-activity cycles, sleep diaries, and circadian chronotypes. In this review, we summarized various circadian misalignments, such as altered light-dark, sleep-wake, rest-activity, fasting-feeding, shift work, evening chronotype, and social jetlag, as well as mutations in clock genes that could contribute to the development of diabetes and poor glycemic status in patients with diabetes. Targeting critical components of the circadian system could deliver potential candidates for the treatment and prevention of type 2 diabetes mellitus in the future.

Diabete mellito dopo trattamento con ocrelizumab per sclerosi multipla primariamente progressiva

Objectives: immune reconstitution therapies, which include antibody-based cell-depleting therapies targeting CD20+ (ocrelizumab, ofatumumab) or CD52+ (alemtuzumab) leukocytes, are approved for the treatment of multiple sclerosis. Autoimmune thyroid disease is the most common adverse effect of treatment with alemtuzumab, but some cases of autoimmune diabetes have been reported. To date, diabetes mellitus has not been reported after CD20-targeting monoclonal antibodies therapy. Case Report: a 41-year-old man with primary progressive multiple sclerosis was diagnosed with diabetes mellitus six months following the first ocrelizumab infusion. He experienced polyuria and polydipsia, but not other symptoms as visual loss or weight loss. We started a basal-bolus insulin therapy, with progressive and relatively rapid improvement of glycemic control. To note, C-peptide resulted indicative of a preserved beta-cell activity and autoantibodies were negative. To present date, the patient reached an excellent control with metformin. Conclusions: this is the first case of diabetes mellitus reported after ocrelizumab administration. The timing of onset and course are similar to alemtuzumab-induced autoimmune diseases, usually interpreted as an “immune reconstitution syndrome”; however, ocrelizumab cell count depletion appears inferior in duration and cell population affected. This case suggests the need for screening and follow-up of glycemic status in patients treated with ocrelizumab. As a novel therapeutic antibody, further investigation is required to elucidate the correlation between hyperglycemia and ocrelizumab.

Impacts of Extra Virgin Olive Oil Consumption on Glycemic Control in Patients with Metabolic Syndrome

The purpose of this study was to observe the impacts of extra virgin olive oil on glycemic control in patients with metabolic syndrome (MetS). A total number of 70 patients of both genders with MetS were selected with the age varying from 35 to 55 years. Among them, 35 patients who had consumed 25 ml of extra virgin olive oil daily for 12 weeks were included in the study group (Group B). Another 35 patients who did not consume extra virgin olive oil, were enrolled as the control group (Group A) for comparison. Levels of fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c) were measured in both the control and study groups at baseline and after 12 weeks. EVOO consumption group showed a statistically significant decrease in fasting blood glucose (p =.003) and glycosylated hemoglobin (p <0.001) in comparison to a control group who did not consume extra virgin olive oil. Regular consumption of extra virgin olive oil improves glycemic status in patients with metabolic syndrome.

RETROSPECTIVE STUDY ON CLINICAL OUTCOME OF STROKE IN RELATION TO ADMISSION DAY GLYCEMIC STATUS IN A TERTIARY CARE HOSPITAL

Stroke or cerebrovascular accident is an abrupt onset of a neurological decit lasting for more than 24hrs that is attributable to a focal vascular cause. Hyperglycemia and stroke appear to be related in two ways. First incidence of stroke is known to be higher in diabetics than non diabetics. Second it has been suggested that even in non diabetics relatively mild degree of hyperglycemia early in stroke might increase infarct size and lead to poor prognosis. A record based retrospective study was conducted at a tertiary care hospital to determine the admission day glycemic status of patients with cerebrovascular accident and to record the outcome. Datas of 30 patients admitted with cerebrovascular accident in the past year was obtained and analysed for demographic and clinical features. It was observed that hyperglycemia was noticed in 63% of patients in general and hyperglycaemia is positively associated with poor functional outcome. Hence, there is an urgent need to conrm the improvement in these patients by normalizing blood sugar

Longitudinal association between periodontal condition and glycaemic status in middle-aged adults: A cross-lagged panel analysis.

To investigate the existence of a bidirectional temporal relationship between periodontal condition and glycaemic status. This longitudinal study included 2198 participants with mean age 43.4 ± 7.7 years, who underwent dental examinations in Yokohama, Japan, at two time points, 2003-2004 and 2008-2009, at an interval of 5 years. Periodontal condition was assessed by the mean value of probing pocket depth (PPD) and clinical attachment level (CAL). Glycaemic status was assessed by fasting glucose and glycated haemoglobin (HbA1c). The cross-lagged panel models showed the effect of HbA1c at baseline on mean PPD at follow-up (β = 0.044, p = .039). There was a marginal effect of fasting glucose on the mean PPD (β = 0.037, p = .059). It was similar to the effect of fasting glucose or HbAlc on mean CAL. However, in the opposite direction, no effect of mean PPD or CAL at baseline on fasting glucose or HbAlc at follow-up was identified. This study demonstrated a unidirectional relationship between glycaemic status and periodontal condition. The study population, however, had mostly mild periodontitis. Future studies are needed to investigate the effect of periodontal condition on glycaemic status in patients with severe periodontitis.

Diabetic Neuropathy, a Cause of Pulmonary Dysfunction in Patients of Type 2 Diabetes Mellitus

Introduction: Diabetic neuropathy (DN) is most commonly associated with diabetic peripheral neuropathy (DPN). About 66% of diabetic patients have either clinical or subclinical neuropathy. Materials and Methods: One hundred and twenty patients were enrolled in our study, 60 patients are of Type 2 diabetes mellitus (T2DM) with neuropathy (DPN), and 60 were of T2DM without neuropathy. They were assessed for neuropathy. Serum fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin A1C (HbA1C), and duration of disease were obtained from the patients. Forced expiratory volume at the 1st s (FEV1) and forced vital capacity were recorded and % FEV1 was calculated. Results: The mean age of T2DM with neuropathy was 49.17 ± 7.1 and in patients of T2DM without neuropathy was 46.63 ± 8.028. The mean value of % FEV1 in T2DM with neuropathy is 95.45 ± 7.16, while in T2DM without neuropathy, it is 83.53 ± 6.22, and the difference was statistically significant. Linear correlation of % FEV1 with fasting plasma glucose (FPG) (r = 0.474, P = 0.008) and HbA1C (r = 0.588, P = 0.001) shows a statistically significant association in diabetic peripheral neuropathy. The standardized β weights of FPG, postprandial plasma glucose, and HbA1C show significant values in patients of DPN. Conclusion: Diabetic peripheral neuropathy (DPN) is associated with decreased pulmonary function as compared to patients of diabetes without neuropathy, the glycemic status of patients may also adversely affect % FEV1. Thus, proper control of hyperglycemia will decrease the further progression of the disease. We also suggest performing pulmonary function test in patients of diabetes mellitus with DN in the preoperative period so as to optimize the perioperative care.

Olea Europaea Effects on Glyco-Metabolic Parameters and on Glycemic Status in Patients with Impaired Fasting Glucose

Aim: the aim of this study was to evaluate the effects of a food supplement based on an infusion of olive leaves and marigold (Olife®) on glyco-metabolic parameters and glycemic status in patients with impaired fasting glucose (IFG). Material and methods: 148 patients were randomized to follow a standardized diet or a standardized diet plus Olife® for 3 months, in an open label, randomized, controlled study design. Olife® was self-administered, once a day, 70 ml/die (about half water glass), during breakfast in addition to diet. Results: in the group treated with Olife® plus diet there was a significant decrease of fasting and post-prandial plasma glucose after 3 months, both compared to baseline, and to diet group. There was a significant decrease of HOMA index in the group treated with Olife® plus diet, both compared to baseline and to diet. At baseline, all patients were affected by IFG. At the end of the study, 21 of 74 patients (28.3 %) returned to a condition of euglycemia according to OGTT in the Olife® plus diet vs 3 of 74 patients (4.1 %) in the diet group. The group treated with Olife® plus diet had an improvement of LDLox and Hs-CRP levels after 3 months, both compared to baseline, and to diet. Conclusions: the study showed the effects of a food supplement based on an infusion of olive leaves and marigold (Olife®) on glyco-metabolic parameters and glycemic status in patients with IFG.

Assessment of glycated hemoglobin levels in non-diabetic subjects with recently diagnosed hypo and hyperthyroidism

Background: Thyroid disorders are highly prevalent in the general population and generally manifest as hypothyroidism or hyperthyroidism. Glycated hemoglobin (HbA1c) is commonly used for the assessment of the long-term glycemic status of diabetic patients. But the HbA1c concentration not only depends on prime glycemia but some other factors. Aims and Objectives: The objective of this study was to measure glycated hemoglobin and thyroid hormone levels and aimed to determine the effects of hypo and hyperthyroidism on glycated hemoglobin in non-diabetic patients. Materials and Methods: This case-control study was conducted on 70 euglycemic individuals each newly diagnosed with hypo and hyperthyroidism. Seventy age and gender-matched controls were recruited. Baseline HbA1c was estimated by high-performance liquid chromatography (HPLC) and thyroid status was measured by chemiluminescent immunoassay (CLIA) method in all cases and controls and then compared. Results: HbA1c values were found to be significantly higher in the hypothyroid group (P < 0.001), whereby its values in hyperthyroid subjects showed no significant difference from controls (P = 0.17). A positive correlation (r=0.67) exists between the levels of thyroid-stimulating hormone (TSH) and HbA1c in hypothyroid patients, but no significant correlation (r= -0.07) was observed for hyperthyroid subjects. Conclusion: HbA1c may not be a reliable indicator of glycemic status in patients with hypothyroidism, and so HbA1c results should be interpreted with caution in such patients.

The Effect of Curcumin on Lipid Profile and Glycemic Status of Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder, some natural compounds are thought to be beneficial in improving the metabolic status of patients with T2DM. Curcumin is the main bioactive agent of turmeric, the impact of curcumin on T2DM is still controversial. This meta-analysis aimed to evaluate the effects of curcumin on lipids profile and glucose status in patients with T2DM. Randomized controlled trials (RCTs) examining the effects of curcumin on lipids profile and glycemic control of T2DM patients were searched in PubMed, Embase, Web of Science and Cochrane Library. Pooled estimates of weighted mean difference (WMD) were calculated between intervention and control groups using random-effects or fixed-effects model. Subgroup and sensitivity analyses were conducted to assess the effects. Nine eligible RCT with 604 subjects were included. The estimated pooled mean changes with curcumin were −18.97 mg/dL (95% CI: −36.47 to −1.47; P=0.03) for triglyceride (TG), −8.91 mg/dL (95% CI: −14.18 to −3.63, P=0.001) for total cholesterol (TC), -4.01 mg/dL (95% CI: -10.96 to 2.95, P=0.259) for low density lipoprotein cholesterol (LDL-c), 0.32 mg/dL (95% CI: −0.74 to 1.37, P=0.557) for high density lipoprotein cholesterol (HDL-c), −8.85 mg/dL (95% CI: −14.4 to −3.29, P=0.002) for fasting blood glucose (FBG), -0.54 (95% CI: −0.81 to −0.27, P ≤ 0.001) for glycated hemoglobin (HbA1c) (%) compared with controls. There was a significant heterogeneity for the influence of curcumin on TG, LDL-c, FBG and HbA1c. Subgroup analysis revealed that the heterogeneity mainly attributed to trial period, curcumin dosage and other therapy. The results of this study showed that curcumin supplementation had beneficial effects on glycemic status and some lipid parameters in patients with T2DM. Further studies with large-scale are still needed to confirm the results.

Effects of Hypertension on Two-Year Outcomes According to Glycemic Status in Patients With Acute Myocardial Infarction Receiving Newer-Generation Drug-Eluting Stents.

The effects of hypertension on long-term outcomes according to glycemic status in patients with acute myocardial infarction (AMI) after successful implantation of newer-generation drug-eluting stents (DES) have not been fully investigated. In this retrospective cohort study, a total of 11,911 patients were classified into 6 groups according to their glycemic status and presence or absence of hypertension. The major outcome was major adverse cardiac events (MACE), defined as all-cause death, recurrent myocardial infarction (Re-MI), or any revascularization. In patients without hypertension, the major outcomes were similar between the normoglycemia and prediabetes groups. However, MACE, all-cause death, cardiac death (CD), Re-MI rates were higher in patients with type 2 diabetes mellitus (T2DM) than in normoglycemic patients. Additionally, Re-MI was higher in patients with T2DM than in prediabetic patients. In patients with hypertension, although the major outcomes were similar between the prediabetes and T2DM groups, in both the prediabetes and T2DM groups, MACE, all-cause death, and CD rates were higher than those in the normoglycemia group. During a 2-year follow-up, the comparable harmful effects of hypertension in patients with AMI and prediabetes or T2DM were observed. Effective blood pressure and glucose control should be strengthened to reduce mortality in these patients.

Serum Adiponectin and Nitric Oxide Levels in Type II Diabetes and Its Correlation With Lipid Profile.

IntroductionVarious markers for diabetes have been identified in this new era of medicine, the most recent being adiponectin, which is primarily secreted from adipose tissue and has anti-diabetic, anti-inflammatory, and anti-atherogenic properties. It is also known to increase insulin sensitivity. Adiponectin deficiency or decreased secretion causes a variety of complications, including insulin resistance and the onset of type 2 diabetes mellitus (T2DM). One such complication of T2DM is endothelial dysfunction, which leads to decreased synthesis of nitric oxide (NO), another potent marker that normally disrupts key events in the progression of atherosclerosis.Aims and objectivesThe aim of the study was to compare and correlate serum adiponectin and nitric oxide levels with glycemic status in patients with T2DM and healthy controls.Materials and methodsThis comparative cross-sectional study included known cases of type II diabetes under group I and healthy age-matched controls under group II. Serum levels of adiponectin and nitric oxide were assessed in both the groups along with glycemic status [fasting blood sugar (FBS) and glycated hemoglobin (HbA1c)] and these parameters were compared between both groups using a t-test. Adiponectin and NO levels were correlated using Pearson’s correlation with glycemic status in group I.ResultsThe mean adiponectin levels in group I were 5.94 ± 1.490 μg/mL, which was significantly (p<0.00) less than in group II, 10.30 ±1.669 μg/mL. The mean NO levels in group I (42.98 ± 6.300 μmol/L) were also significantly (p<0.00) less than in group II (56.126 ± 7.579 μmol/L). FBS and HbA1C levels were significantly higher in group I than in group II.ConclusionAdiponectin and NO levels were significantly reduced in individuals with T2DM when compared to healthy controls. Therapeutic interventions that increase adiponectin and NO levels may be useful targets for improving diabetes control and reducing complications.

Family support and associated with glycemic status in patients with type 2 diabetes mellitus

Diabetes mellitus is a disease that can cause sufferers to experience an increase in blood glucose levels in their body. Increased blood glucose levels can be prevented by implementing self-care routinely and getting support from the family. Objective: To find out there is a relationship between the family support with glycemic status in patients with type 2 diabetes at the Banyuanyar Health Center. Methods: Using a descriptive quantitative correlation research with a cross-sectional approach. The population of this study were patients with type 2 diabetes mellitus at the Banyuanyar Health Center as many as 469 people. Sampling technique using probability sampling with simple random sampling obtained a large sample of 99 respondents. Data collection by using a questionnaire. Data analysis using Pearson Product Moment. Results: 77 respondents had sufficient family support and 68 respondents had diabetes mellitus on their glycemic status. The results of the analysis show that there is a significant relationship between family support and glycemic status where the significant value (p-value) is 0.0001 &lt;0.05. The correlation coefficient value between family support and glycemic status is -0. There is a relationship between the family support and associated with glycemic status (p-value 0.0001). Conclusion: There is a relationship between the family support and associated with glycemic status in type 2 DM patients at the Banyuanyar Health Center.

Associations between HbA1c-derived estimated average glucose and fasting plasma glucose in patients with normal and abnormal hemoglobin patterns

Fasting plasma glucose (FPG) and HbA1c are well-known tests for monitoring short and long-term glycemic control, respectively. Estimated average glucose (eAG) is derived from the HbA1c for expression in the same units as FPG. The present study aimed to evaluate the association between eAG and FPG values. This retrospective study was performed on 1285 patients who measured the FPG and HbA1c (capillary electrophoresis method) values on the same day. They were initially divided into 3 hemoglobin-pattern groups, normal, HbE, and high HbA2, and then these 3 groups were further subdivided into whole group, subgroup 1 (HbA1c ≤ 7%) and subgroup 2 (HbA1c >7%) for analytical comparisons. The eAG values were calculated using Nathan’s equation. The differences, agreements, and correlations between eAG and FPG were evaluated. Good agreements and strong positive correlations between eAG and FPG values were observed in all 3 whole groups. In subgroup analysis, the degrees of agreement and correlation depended on the level of glycemic control, as all associations became stronger with better glycemic control. Additionally, the HbA1c levels and different eAG-FPG values between the normal and other groups were not significantly different in either whole group or subgroup comparisons. Our study found good agreements and strong positive correlations between eAG and FPG in all groups, indicating that high HbA2 or HbE did not affect the HbA1c levels or thus the associations between eAG and FPG. Reporting the eAG together with the HbA1c value should help improve the understanding of glycemic status in patients, leading to improved blood glucose control.

Novel Insight into the Mechanism of Metabolic Surgery Causing the Diversity in Glycemic Status in Type 2 Diabetes.

Metabolic surgery results in diverse glycemic status in patients with type 2 diabetes (T2D), including hyperglycemia without remission, significant amelioration of hyperglycemia with partial remission, complete restoration of euglycemia, or with prolonged remission, hyperglycemia recurrence in relapses after remission, or post-bariatric hypoglycemia. Unfortunately, it is not known how metabolic surgery leads to this diverse consequence. Here, we discuss the diversity of glycemic status associated with metabolic surgery and the potential mechanisms of T2D remission. We also highlight the relationship between the change in low-grade inflammation and T2D remission after metabolic surgery. We hypothesize that the level of inflammatory and anti-inflammatory cytokines controls the efficacy of metabolic surgery in patients with T2D. This hypothesis may provide further insight into the mechanism of the beneficial effects of metabolic surgery patients with T2D.

Effect of COVID-19 lockdown on glycemic status of patients with T2DM and effects of various factors involved

Background: The recent coronavirus disease 2019 lockdowns forced people to stay indoors, resulting in lower physical activity, and change in dietary patterns, impacting glycemic control in the diabetic population. We aimed to assess the impact of the 3-month lockdown on glycemic control among outpatients with type 2 diabetes (T2DM) being treated at our hospital. Study Design: This retrospective study included data of outpatients aged ≥30 years with preexisting T2DM, regularly attending the clinic during the prelockdown period and who came for follow-up postlockdown. The primary outcome measures were change in glycated hemoglobin (HbA1c), fasting blood glucose sugar (FBG), and postprandial blood sugar (PPBG) compared to the last value before the lockdown. Results: A total of 200 (male: female – 83:117) patients with a mean (standard deviation [SD]) age of 58.0 (10.8) years were included. The mean (SD) interval between the pre- and post-lockdown visit was 3.9 (0.9) months, and 58.5% of the patients were compliant with the medication. The mean HbA1c levels increased significantly by 1.1 (P = 0.000), FBG by 21.9 mg/dL (P = 0.000), PPBG by 28.0 mg/dL (P = 0.000), and weight by 1.6 kg (P = 0.000), from pre- to post-lockdown visit. The patients noncompliant to therapy had a significantly higher increase in glycemic parameters. The results showed a significant correlation between the interval of follow-up and treatment compliance with increase in glycemic parameters and weight. Conclusion: The results of this study revealed that there was a negative impact of lockdown on glycemic control in T2DM patients, highlighting the need for telehealth strategies to ensure the well-being of diabetic patients during such calamities.

MECHANICAL VENTILATION NEED AND GLYCEMIC STATUS IN PATIENTS WITH COVID -19: A FOLLOW-UP STUDY.

Diabetes mellitus is a well known risk factor for COVID-19 patients. However, There is limited data to investigate the association between prediabetes and COVID-19. We aimed to evaluate the effect of prediabetes and mechanical ventilation on the course of COVID-19 and determine whether patients who recover from COVID-19 infection show changes in cardiac function and laboratory findings during follow-up. This study included 87 adult patients who were diagnosed with COVID-19 according to the WHO definition and were admitted for inpatient treatment between April 2021 and August 2021. They were classified into 3 groups, normoglycemia (n=40), prediabetes (n=25), and diabetes (n=22), and then divided into groups according to need for mechanical ventilation. Statistical analyses were performed to compare laboratory, echocardiographic findings and COVID-19 outcomes among the groups. The need of mechanical ventilation was significantly higher in both diabetes and prediabetes groups than the normoglycemic group. Patients with diabetes and prediabetes had significantly higher LV E/Em (p=0.003, p=0.045) and RV MPI (p=0.032, p=0.021) and significantly shorter PAT (p=0.001, p=0.036) and significantly longer RV IVRT (p=0.021, p=0.017), respectively, compared to the normoglycemia group. Patients who required mechanical ventilation had significantly higher CRP (p=0.043), troponin (p<0.001), ferritin (p<0.001), HBA1C (P<0.001), glucose (p=0.019), monocytes (p<0.001), and monocytes-HDL ratio (MHR) (p<0.001) and significantly lower levels of HDL-C (p<0.001). Glucose, HDL-C, troponin, MPV, NLR, PLR level and RV and E/Em were found independently associated with the RVMPI. Prediabetes was associated with more impaired LV and RV diastolic functions compared to normoglycemic patients, comparable to those seen in diabetes. Our observations suggest that prediabetes should be considered as diabetes in the risk stratification of patients with COVID-19.

Сахарный диабет и хронический пародонтит: двунаправленная связь

Today, scientists are identifying more complex links between diabetes mellitus and chronic periodontitis, and also indicate a bi-directional relationship between these two diseases, each of which negatively affects other. According to many sources, there is a confirmation of relationship between periodontal disease and glycemic status, expressed through glycosylated hemoglobin and glucose. The risk of developing chronic periodontitis increases 2–3 times in people with diabetes as compared to people without this pathology. In common with other complications of diabetes mellitus, the risk of developing and progression of chronic periodontitis increases with the deterioration of the glycemic profile. People with chronic periodontitis have higher levels of glycosylated hemoglobin. New evidence indicates that individuals with severe periodontitis have an increased risk of developing type 2 diabetes. Studie have been carried out to determine the effect of chronic periodontitis on the progression of diabetes mellitus, in which there has been a tendency to a decrease in glycemic status in patients with type 2 diabetes mellitus after correction of chronic periodontal disease. However, the exact mechanisms that lead to a decrease in glycemic hemoglobin and an improvement in glycemic control after periodontal treatment in people with type 2 diabetes mellitus are currently not entirely clear and require extensive study.